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PreviewsClearly it will be important to try to find
more examples of these different con-
formers of TCR Va or Vb in TCRs binding
to different ligands in order to gauge the
relevance of the open conformers to TCR
specificity and repertoire.
TCR repertoire generation has never
before been accused of thriftiness. The
potential of a T cell to get three different
binding structures out of a single TCR
shows that the profligacy of a T cell’s
misspent thymic youth—when many
TCRs are tried out, but most are either
dangerous or useless—can be amelio-
rated in the T cell’s maturity by making
the best use of the options that are left.REFERENCES
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Unc93B1, a multitransmembrane ER-resident protein, controls intracellular trafficking of endosomal Toll-like
receptors. In this issue of Immunity, Fukui et al. (2011) revealed that Unc93B1 regulates differential transport
of TLR7 and TLR9 into signaling endosomes to prevent autoimmunity.Endosomal Toll-like receptors (TLRs)
recognize viral nucleic acids and induce
activation of antiviral genes. Upon endo-
cytosis of virions, TLR9 binds to double-
stranded DNA (dsDNA) rich in unmethy-
lated CpG motifs found in DNA viruses,
and TLR7 recognizes single-stranded
RNA (ssRNA) with GU-rich sequences
found in viral RNA. However, such
molecular patterns associated with viral
nucleic acids are not necessarily unique
to viruses, because mammalian nucleic
acids also share features that are recog-
nized by these TLRs. Under certain
circumstances, self nucleic acids can
accidentally enter the endosome and
trigger TLR7 and TLR9, which can lead
to autoimmune diseases including psori-
asis, arthritis, and systemic lupus erythe-
matosus (SLE) (Marshak-Rothstein and
Rifkin, 2007). The innate immune system
has in place multiple regulatory mecha-nisms to prevent recognition of self
nucleic acids. One such mechanism in-
volves regulation of TLR intracellular
trafficking. At steady state, the majority
of TLR7 and TLR9 are expressed in the
endoplasmic reticulum (ER) (Figure 1).
Upon viral infection or TLR signaling,
TLR7 and TLR9 are mobilized to traffic
from the ER to the endosomes where viral
recognition takes place. A multitrans-
membrane protein found in the ER at
steady state, Unc93B1, controls traffick-
ing of all endosomal TLRs, TLR3, 7, 8,
and 9 (Kim et al., 2008). Subcellular local-
ization of TLR7andTLR9 is regulated such
that these receptors are confined to the
endosomes and are excluded from the
plasma membrane, where self nucleic
acids are accessible. An additional level
of control is provided by the fact that
TLR7 and TLR9 are active only once they
are cleaved in the acidified ‘‘signalingendosomes’’ by endosomal proteases
(Figure 1; Barton and Kagan, 2009).
Once within the signaling endosomal
compartment, TLR9 and TLR7 recruit the
adaptor proteinMyD88 and trigger signals
leading to inflammatory cytokine expres-
sion through NF-kB activation. These
receptors are further transported to lyso-
some-related organelle by the adaptor
protein-3 (AP-3) complex, enabling them
to recruit interferon regulatory factor-7
(IRF7) and activate transcription of type I
interferon (IFN) genes (Sasai et al., 2010).
However, how the relative distribution of
TLR7 and TLR9 in the signaling endo-
somes within the same responding cell is
coordinated has remained unclear.
The current study by Fukui et al. (2011)
builds on their previous finding that
TLR9 competes with TLR7 for Unc93B1-
dependent transportation to signaling
endosomes (Fukui et al., 2009) andnity 35, July 22, 2011 ª2011 Elsevier Inc. 3
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Figure 1. Unc93B1 Control of TLR7 and TLR9 Trafficking into Signaling Endosomes
B cells, plasmacytoid DCs, DCs, and macrophages express TLR7 and TLR9. At steady state, the majority of TLR7 and TLR9 reside in the ER in cells expressing
WT Unc93B1. Upon TLR stimulation, TLR9 is preferentially transported through the early endosome to the acidified endosomes by Unc93B1, whereby it is
cleaved to become competent for signaling. In contrast, D34A mutant Unc93B1 transports TLR7, but not TLR9, to the signaling endosome even in the absence
of external stimuli. Stimulation of TLR7 by endogenous RNA ligands results in B cell-dependent Th1 and Th17 cell differentiation, which leads to splenomegaly
with myeloproliferation, thrombocytopenia, hepatic necrosis, and death.
Immunity
Previewsreports an exuberant systemic inflamma-
tion that results from a dysregulation
of this process in vivo. Previously, the
same group used complementation clon-
ing with a TLR7-unresponsive cell line and
found that amino acid D34 in Unc93B1
repressed TLR7-mediated responses.
Cells expressing D34A mutant Unc93B1
are hyperresponsive to TLR7 ligands but
hyporesponsive to TLR9 ligands, because
of preferential binding and trafficking
of TLR7 into signaling endosomes (Fig-
ure 1; Fukui et al., 2009). In the current
study, the authors generated genetically
targeted mice harboring a D34A mutation
in Unc93B1. Remarkably, these mice
developed severe lethal inflammatory
disease. In the absence of any other auto-
immune-predisposing mutations, half of
the D34A homozygous genetically tar-
geted mice died before 30 weeks of age
because of liver necrosis, with no obvious
necrosis in other organs including kidney,
lung, heart, and spleen. D34A mutant4 Immunity 35, July 22, 2011 ª2011 Elseviermice developed progressive spleno-
megaly with massive expansion of eryth-
roblasts and myeloid cells, as well as
severe thrombocytopenia. Moreover,
autoantibody production was detected
in some of these mice. To probe the path-
ogenesis, D34A genetically targeted
mice were crossed to a variety of geneti-
cally ablated mice. TLR7 and MyD88
deficiency completely prevented disease
development in D34A mice, whereas
TLR9 deficiency only partially reversed
the inflammatory phenotype. D34A
genetically targeted mice spontaneously
developed Th1 and Th17 cell responses,
which were abrogated by TLR7 defi-
ciency. Lymphocytes were required for
the disease observed in D34A mice,
because the D34A mutation on a Rag2/
background completely eliminated in-
flammatory disease. Strikingly, B cells
were required for the pathogenesis in
D34A mice, as indicated by the fact that
D34A mice crossed onto the B cell-defi-Inc.cient Ighm/ background did not suffer
from inflammatory disease and lacked
spontaneous activation of Th17 cell
responses. Because antibody is not
required for autoreactive T cell activation
in MRL/lpr mice (Chan et al., 1999) and
because only a mild increase in IgG2a
and IgG2b amounts were observed in
D34A genetically targeted mice (Fukui
et al., 2011), the pathogenic role of B cells
probably stems from their capacity to
present autoantigens to T cells.
Intracellular distribution analysis of
TLRs in D34A genetically targeted mice
revealed that,whereasTLR9 remainedex-
cluded from lysosomal-associated mem-
brane protein-1 (LAMP1)+ compartment,
TLR7 was confined almost exclusively to
the LAMP1+ compartment in bone
marrow-derived DCs, even in the absence
of any external stimulus. These data indi-
cate that the D34A mutant Unc93B1 not
only enables preferential trafficking of
TLR7 to the endosome but also overrides
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delivery (Figure 1). This could at least in
part explain the severe autoimmune
phenotype seen in D34A genetically tar-
geted mice. On the scale of autoimmune
diseases, D34A genetically targeted mice
rate at the severe end—as pathogenic as
in TLR7 transgenic mice carrying 8–16
extra copies of the TLR7 gene, which
also develop splenomegaly, thrombocy-
topenia, liver inflammation, and death
(Deane et al., 2007). Even though TLR
expression was unaltered in these mice,
pathology in the D34A mutant mice was
far beyond the SLE-like diseases seen in
the Y-linked autoimmune accelerating
(Yaa) model with TLR7 gene duplication,
or MRL/lpr mice. These results indicate
that not only the dosage, but also the
subcellular location of TLR7, is strictly
regulated to avoid autoimmune disease,
in this case, by Unc93B1.
An obvious question that arises from
these findings reported here (Fukui et al.,
2011) is why TLR7, but not TLR9, stimula-
tion results in autoimmune outcomes.
This dichotomy is evenmore exaggerated
in the case of autoimmune-prone MRL/lpr
mice, where TLR9 ameliorates disease
progression (Christensen et al., 2006)
and the protective role for TLR9 depends
on its antagonism of TLR7 (Nickerson
et al., 2010). First, although downstream
signaling is assumed to be the same
between TLR7 and TLR9, this has not
been formally tested. If TLR7 and TLR9
can form heterodimers, downstream
signaling can be regulated by the ratio of
homo- versus heterodimers. Second, it
is possible that endogenous TLR7 ligands
are more abundant and/or potent in in-
ducing signals compared to TLR9 ligands.
Third, it is also possible to imagine
a scenario in which two separate cell
types are involved—e.g., cells expressing
TLR7 selectively induce transcriptionprogram that leads to overt inflammation
in contrast to those expressing TLR9.
However, the current study highlights
that within the same responding cell,
competition over Unc93B1 binding by
TLR7 and TLR9 can have a profound
consequence after recognition of endog-
enous nucleic acids.
These results also provide a platform
with which to investigate the endogenous
ligands responsible for activating TLR7
and the cell types responsible for patho-
genesis of various autoimmune diseases.
The pathogenic role of B cells in this re-
gard is particularly interesting, and future
studies are needed to probe whether
cell-intrinsic or -extrinsic requirements for
B cell TLR signaling leads to autoimmune
T cell activation. In addition to B cells,
involvement of plasmacytoid dendritic
cells, dendritic cells, and macrophages
that also express these TLRs needs to be
clarified. Even though the D34A mutation
is not known to occur naturally in humans,
whether other single-nucleotide polymor-
phisms (SNPs) within the Unc93b1 gene
or those that affect TLR trafficking in
general are associated with autoimmune
diseases in humans remains an intriguing
question for future studies.
Finally, an evolutionarily relevant ques-
tion that emerges from these findings
is why viral-sensing TLRs and not bacte-
rial TLR sensors need be coregulated.
Bacterial pathogen-associated molecular
patterns (PAMPs) have unique molecular
signatures that are absent from mamma-
lian cells, and TLRs that recognize these
do not require an additional level of regu-
lation among the receptors. In contrast,
viral PAMPs are shared by endogenous
nucleic acids and require an additional
level of regulation. Such coregulation of
TLR7 and TLR9 may have evolved to be
optimized to avoid stimulation when they
collectively sense the relative abundanceImmuof RNA to DNA from endogenous sources
(i.e., dead cells) but can still engage
robust activation when RNA or DNA
predominates during a virus infection. In
this regard, D34A mutant Unc93B1 also
preferentially binds TLR8 and TLR13
compared to WT Unc93B1 (Fukui et al.,
2009), indicating that coregulated traf-
ficking by Unc93B1 extends to RNA
(TLR7, TLR8, and potentially TLR13)
versus DNA (TLR9) sensing TLRs. There-
fore, the love triangle between Unc93B1,
TLR7, and TLR9 may indeed involve
more partners and much remains to be
seen how attraction between these
nucleic acid-sensing TLRs play out in
keeping us out of fatal attraction.
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